JUST THE FACTS

Get the facts about FLUMIST QUADRIVALENT

Fact 1:

FLUMIST QUADRIVALENT is designed not to cause the flu.1 Like the vaccines for chicken pox and measles, FLUMIST QUADRIVALENT contains weakened, live viruses. Because the viruses in the vaccine are weakened, they cannot cause the flu.2

Fact 2:

Your patients cannot catch the flu from someone who was just vaccinated with FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT contains weakened live viruses that have been modified and will not cause the flu.3

Fact 3:

Your patients can breathe normally during administration of FLUMIST QUADRIVALENT.2 Sniffing is NOT necessary. It is OK if your patients sneeze, swallow, or if dripping occurs.4

Fact 4:

Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT was not studied in people with severe asthma or active wheezing.2

Fact 5:

Patients who sneeze or blow their nose during administration of FLUMIST QUADRIVALENT, do not need to be revaccinated. Dripping down the throat, sneezing, or swallowing sometimes happens after vaccination.4

Fact 6:

Patients with a minor illness (eg, diarrhea or mild upper respiratory tract infection with or without fever) can still be vaccinated with FLUMIST QUADRIVALENT. Patients with severe nasal congestion that might limit delivery of the vaccine to the nasal lining should wait until they are less congested to get FLUMIST QUADRIVALENT or should be vaccinated with another appropriate flu vaccine.1

Fact 7:

People with a weakened immune system or those who live with a person with a severely weakened immune system may not be eligible for FLUMIST QUADRIVALENT. If your patient is in close contact with a person with a weakened or severely weakened immune system, you need to use your clinical judgment to determine if FLUMIST QUADRIVALENT is appropriate for them.2

IMPORTANT SAFETY INFORMATION


  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.